ReviewBMC neurology2025
Paraneoplastic cochleovestibulopathy associated with breast cancer: a case report of two patients and literature review.
Review in BMC neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundParaneoplastic cochleovestibulopathy (PCVP) is a rare, atypical neurological paraneoplastic syndrome of the nervous system that is often misdiagnosed and mistreated. CASE PRESENTATION: We report two cases of middle-aged women who presented with bilateral sensorineural hearing loss (SNHL) as the initial symptom. Pure-tone audiometry (PTA) demonstrated bilateral hearing impairment, while brainstem auditory evoked potentials (BAEP) and cochlear electrograms were within normal limits. Otoacoustic emissions indicated bilateral cochlear dysfunction. Cranial imaging excluded intracranial organic and vascular lesions. After corticosteroid therapy proved ineffective, positron emission tomography/computed tomography (PET/CT) combined with histopathological examination confirmed the presence of breast cancer, leading to a diagnosis of PCVP. Despite receiving endocrine therapy (Case 1) or surgical excision (Case 2), neither patient exhibited significant improvement in PTA during one year of follow-up.
conclusionPCVP should be considered in middle-aged patients who present with progressive bilateral hearing loss, often accompanied by vestibular dysfunction and clinical signs of cerebellar or brainstem involvement. Regular monitoring with PET/CT is recommended, and female patients in particular should undergo screening for breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.